Jack Meehan

In the month since Quest Diagnostics Inc (NYSE: DGX) announced a strategic partnership with UnitedHealth Group Inc (NYSE: UNH), the stock has garnered a slew of upgrades. The Rating Barclays analyst Jack Meehan upgraded Quest to Overweight and raised his price target from $120 to $130. The Thesis...

Shares of Illumina, Inc. (NASDAQ: ILMN) hit a new 52-week high of $198.47 Wednesday and ended the day higher by nearly 15 percent after the company reported top- and bottom-line beats in its second-quarter earnings report. However, the results weren't good enough for analysts at Barclays who are...

On December 22, CMS announced its year-end coverage decisions for Myriad Genetics, Inc. (NASDAQ: MYGN), including the non-coverage of Vectra DA. Barclays’ Jack Meehan maintains an Equal-Weight rating on the company, with a price target of $22. Surprising Decision Expressing surprise at the...

Following Illumina, Inc. (NASDAQ: ILMN)'s negative pre-announcement after the market close Monday, Barclays said same issues continue to plague the company, which has made negative pre-announcements in three of the past five quarters. Same Issues, New Issues Barclays indicated the weakness was...

Barclays found that TESARO Inc (NASDAQ: TSRO)'s final stage results on NOVA and its indication to pursue a wider label for the drug means a setback for Myriad Genetics, Inc. (NASDAQ: MYGN) and its myChoice HRD. As a result, Myriad stock traded down by more than 7 percent on Monday. The firm reduced...

In a note released Monday, Barclays said about four companies sought to bid for Cepheid (NASDAQ: CPHD). This follows a review of the proxy statement released by the company last Friday regarding its announced acquisition by Danaher Corporation (NYSE: DHR) for $4 billion or $53 per share. Jack...

Shares of Hologic, Inc. (NASDAQ: HOLX) rose about 1 percent in the Friday pre-market hours after Barclays upgraded the shares to Overweight from Equal Weight, saying the company can grow "stronger for longer" versus its previous expectations. The brokerage, who also upped the price target by $2 to...

Barclays said Laboratory Corp. of America Holdings (NYSE: LH) management noted it sees some sustainable tailwinds for volume growth in its lab business, while reimbursement visibility remains good through the end of 2017. Analysts, including Jack Meehan who had investor meetings with LabCorp...

Barclays’ Jack Meehan expressed concern regarding the competitive weakness in Myriad Genetics, Inc.’s (NASDAQ: MYGN) Hereditary Cancer Testing (HCT) business, expecting it to pressure the company’s overall results. Meehan downgraded the rating on the company from Overweight to...

Barclays has maintained its Equal-Weight rating on Hologic, Inc. (NASDAQ: HOLX) shares despite strong third quarter results as it expects tough comps in the coming quarters. Hologic delivered a better top line, driving a $0.04 beat relative to the Street. Overall revenues came in 2.4 percent better...

Agilent Technologies Inc (NYSE: A) filed its FY2Q16 Form 10-Q on June 7, 2016. Barclays’ Jack Meehan maintained an Equal-Weight rating for the company, with a price target of $45. Following a review of the 10-Q filing, the analyst enumerated the following observations: As of April 30,...